{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:05:25Z","timestamp":1780355125664,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40264-021-01101-y","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T09:02:37Z","timestamp":1627549357000},"page":"1007-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comment on: \"Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)\""],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5735-9530","authenticated-orcid":false,"given":"Alain","family":"Braillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"1101_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40264-020-01005-3","volume":"44","author":"P Bahri","year":"2021","unstructured":"Bahri P, Morales DR, Inoubli A, Dogn\u00e9 JM, Straus SMJM. Proposals for engaging patients and healthcare professionals in risk minimisation from an analysis of stakeholder input to the EU valproate assessment using the novel analysing stakeholder safety engagement tool (ASSET). Drug Saf. 2021;44:193\u2013209.","journal-title":"Drug Saf"},{"key":"1101_CR2","doi-asserted-by":"publisher","first-page":"e014719","DOI":"10.1136\/bmjopen-2016-014719","volume":"7","author":"M Harrison","year":"2017","unstructured":"Harrison M, Milbers K, Hudson M, Bansback N. Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. BMJ Open. 2017;7:e014719.","journal-title":"BMJ Open"},{"key":"1101_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40290-019-00304-0","volume":"33","author":"T Madison","year":"2019","unstructured":"Madison T, Donner B, Mutter R, Mingrino R, Alvaro G. Effectiveness of risk minimization measures to prevent pregnancy exposure to mycophenolate-containing medicines in Europe. Pharm Med. 2019;33:395\u2013406.","journal-title":"Pharm Med."},{"key":"1101_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40264-019-00874-7","volume":"43","author":"CE Hoeve","year":"2020","unstructured":"Hoeve CE, Francisca RDC, Zomerdijk I, Sturkenboom MCJM, Straus SMJM. Description of the risk management of medication errors for centrally authorised products in the European Union. Drug Saf. 2020;43:45\u201355.","journal-title":"Drug Saf"},{"key":"1101_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40264-020-00993-6","volume":"44","author":"RDC Francisca","year":"2021","unstructured":"Francisca RDC, Baba E, Hoeve CE, Zomerdijk IM, Sturkenboom MCJM, Straus SMJM. Introduction or discontinuation of additional risk minimisation measures during the life cycle of medicines in Europe. Drug Saf. 2021;44:63\u201372.","journal-title":"Drug Saf"},{"key":"1101_CR6","unstructured":"European Medicine Agency. Assessment report: procedure under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data. Substances related to valproate. EMA\/686022\/2014. 2014. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-related-substances-article-31-referral-prac-assessment-report_en.pdf. Accessed 6 Mar 2020."},{"key":"1101_CR7","unstructured":"Jouan A. An antiepileptic in the turmoil. 2015. https:\/\/sante.lefigaro.fr\/actualite\/2015\/05\/20\/23753-antiepileptique-dans-tourmente. Accessed 6 Mar 2020."},{"key":"1101_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111470","author":"PC G\u00f8tzsche","year":"2021","unstructured":"G\u00f8tzsche PC, J\u00f8rgensen KJ. EMA\u2019s mishandling of an investigation into suspected serious neurological harms of HPV vaccines. BMJ Evid Based Med. 2021. https:\/\/doi.org\/10.1136\/bmjebm-2020-111470.","journal-title":"BMJ Evid Based Med."},{"key":"1101_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2165\/11318980-000000000-00000","volume":"32","author":"TJ Giezen","year":"2009","unstructured":"Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Saf. 2009;32:1175\u201387.","journal-title":"Drug Saf"},{"key":"1101_CR10","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/pds.4196","volume":"26","author":"JC Bouvy","year":"2017","unstructured":"Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005\u20132013. Pharmacoepidemiol Drug Saf. 2017;26:1442\u201350.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1101_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40264-018-0729-0","volume":"42","author":"A Kant","year":"2019","unstructured":"Kant A, de Vries L, Rolfes L. Surveillance of drug safety during pregnancy: insight in current international activities, future intentions and need for support of National Pharmacovigilance Centres. Drug Saf. 2019;42:35\u201343.","journal-title":"Drug Saf"},{"key":"1101_CR12","unstructured":"Prescrire International. Towards better patient care: drugs to avoid in 2021. Prescrire Int. 2021;30(223):5_1\u201351_10. https:\/\/english.prescrire.org\/en\/81\/168\/60654\/0\/NewsDetails.aspx. Accessed 8 Feb 2021."},{"key":"1101_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12916-014-0262-7","volume":"13","author":"IJ Onakpoya","year":"2015","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Med. 2015;13:26.","journal-title":"BMC Med"},{"key":"1101_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/11586620-000000000-00000","volume":"34","author":"JJ Borg","year":"2011","unstructured":"Borg JJ, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011;34:187\u201397.","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01101-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01101-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T15:27:44Z","timestamp":1629214064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01101-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01101-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"assertion":[{"value":"4 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AB is among the industry-independent experts from Jeanne Lenzer\u2019s list (). In 2011, MM created an umbrella association (Association to Help Parents of Children Suffering from Anti-Convulsant Syndrome. APESAC), being the mother of two children who were consecutively damaged by valproate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N\/A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"N\/A.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AB and MM equally participated in the conception of this article. AB drafted the manuscript, MM revised it critically, both gave final approval of the version submitted.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}